Canal-U

 

Résultats de recherche

Nombre de programmes trouvés : 29
Label UNT Conférences

le (19m4s)

Non-inferiority, superiority, or both? Operationalizing the FDA guidance

Title : Non-inferiority, superiority, or both? Operationalizing the FDA guidanceSpeaker: Marc PFEFFER, Boston, USADiscussant: Stuart POCOCK, London, GBRRegulatory viewpoint: Kristina DUNDER, EMEA, SWEAbstract : Non-inferiority, superiority, or both? Operationalizing the FDA guidanceL’auteur n’a pas transmis de conflit d’intérêt concernant les données diffusées dans cette vidéo ou publiées dans la référence citée.Conférence enregistrée : 9th Global Cardiovascular Clinical Trialists Forum • Paris 2012 Diabetes clinical trials : helped or hindered by the current shift in regulatory requirements? Glycaemic control is an inadequate surrogate marker of cardiovascular event reduction in patients with type 2 diabetes. Clinical trials to date have been unsuccessful in identifying ...
Voir la vidéo
Label UNT Conférences

le (15m47s)

Cardiovascular Clinical Trialists (CVCT) Forum - Paris 2012 : Non-inferiority, superiority, or both? Operationalizing the FDA guidance

Title: Cardiovascular Clinical Trialists (CVCT) Forum - Paris 2012 : Non-inferiority, superiority, or both? Operationalizing the FDA guidanceSpeaker: Marc PFEFFER, Boston, USADiscussant: Stuart POCOCK, London, GBRRegulatory viewpoint: Kristina DUNDER, EMEA, SWEAbstract : Non-inferiority, superiority, or both? Operationalizing the FDA guidanceL’auteur n’a pas transmis de conflit d’intérêt concernant les données diffusées dans cette vidéo ou publiées dans la référence citée.Conférence enregistrée : 9th Global Cardiovascular Clinical Trialists Forum • Paris 2012 Diabetes clinical trials : helped or hindered by the current shift in regulatory requirements? Glycaemic control is an inadequate surrogate marker of cardiovascular event reduction in patients with type 2 diabetes. Clinical ...
Voir la vidéo
Label UNT Conférences

le (9m19s)

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Impact of major clinical trials on ESC Chronic Heart Failure 2012 guidelines. Game changer trials: EMPHASIS-HF, SHIFT, Devices…

... also important, differences in recommendations may act as a barrier to guideline. The NICE CHF guidance was updated in 2010, and it is not likely to be revised in short term.Practice differs from the guideline recommendations. Registries suggest...
Voir la vidéo
Label UNT Conférences

le (13m12s)

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Impact of major clinical trials on ESC Chronic Heart Failure 2012 guidelines. Game changer trials: EMPHASIS-HF, SHIFT, Devices…(debates).

... is also important, differences in recommendations may act as a barrier to guideline. The NICE CHF guidance was updated in 2010, and it is not likely to be revised in short term.Practice differs from the guideline recommendations. Registries suggest...
Voir la vidéo

 
Cerimes